Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain

Expert Reviews in Molecular Medicine

Volumn 14, Issue , 2012, Pages

  Patel, Aarti N ^a   Jhamandas, Jack H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1' (2 METHYLBENZYL) 1,4' BIPIPERIDIN 4 YL] 1H BENZO DEXTRO IMIDAZOL 2(3H) ONE; AC 187; AC 253; ADVANCED GLYCATION END PRODUCT RECEPTOR; AF 267B; AMYLIN RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BRAIN RECEPTOR; BUNGAROTOXIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIRAGLUTIDE; MEMANTINE; METABOTROPIC RECEPTOR 5; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROTROPHIN RECEPTOR P75; OLIGOMER; RECEPTOR BLOCKING AGENT; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAL 8; CELL SURFACE RECEPTOR;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; LONG TERM POTENTIATION; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; HUMANS; NEURONS; RECEPTORS, CELL SURFACE;

EID: 84859070489     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399411002134     Document Type: Review

References (184)

1. Li, S.F. et al. (2011) Requirement of alpha7 nicotinic acetylcholine receptors for amyloid beta proteininduced depression of hippocampal LTP in CA1 region of rats in vivo. Synapse 65, 1136-1143
2. Lacor, P.N. et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. Journal of Neuroscience 27, 796-807 (Pubitemid 46174498)
3. Selkoe, D.J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791
4. Citron, M. (2010) Alzheimer's disease: Strategies for disease modification. Nature Reviews. Drug Discovery 9, 387-398
5. Wenk, G.L. (2003) Neuropathologic changes in Alzheimer's disease. Journal of Clinical Psychiatry 64 (Suppl 9), 7-10
6. Glenner, G.G. and Wong, C.W. (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysics Research Communications 120, 885-890 (Pubitemid 14104991)
7. Gralle, M. and Ferreira, S.T. (2007) Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. Progress in Neurobiology 82, 11-32 (Pubitemid 46719589)
8. Selkoe, D.J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends in Cell Biology 8, 447-453
9. Selkoe, D.J. et al. (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Annals of the New York Academy of Sciences 777, 57-64 (Pubitemid 26149170)
10. Lambert, M.P. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 95, 6448-6453
11. Gong, Y. et al. (2003) Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 100, 10417-10422 (Pubitemid 37071893)
12. Walsh, D.M. et al. (2002) Naturally secreted oligomers of amyloid [beta] protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (Pubitemid 34288854)
13. Lambert, M.P. et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 95, 6448-6453
14. Lesné, S. et al. (2006) A specific amyloid-[beta] protein assembly in the brain impairs memory. Nature 440, 352-357
15. Georganopoulou, D.G. et al. (2005) Nanoparticlebased detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proceedings of the National Academyof Sciences of the United States of America 102, 2273-2276 (Pubitemid 40279365)
16. Dineley, K.T. et al. (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. Journal of Neuroscience 21, 4125-4133 (Pubitemid 32538537)
17. Snyder, E.M. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-[beta]. Nature Neuroscience 8, 1051-1058 (Pubitemid 41061516)
18. Wang, H.Y. et al. (2000) beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. Journal of Biological Chemistry 275, 5626-5632
19. Zhao, W.-Q. et al. (2010) Inhibition of calcineurinmediated endocytosis and a-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid β oligomer-induced synaptic disruption. Journal of Biological Chemistry 285, 7619-7632 20
20. De Felice, F.G. et al. (2009) Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proceedings of the National Academy of Sciences of the United States of America 106, 1971-1976
21. Xie, L. et al. (2002) Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. Journal of Neuroscience 22, RC221
22. Renner, M. et al. (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754
23. Wang, Q. et al. (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun Nterminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. Journal of Neuroscience 24, 3370-3378 (Pubitemid 38451902)
24. Iwatsubo, T. et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with endspecific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 13, 45-53
25. Fraering, P.C. (2007) Structural and functional determinants of gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. Current Genomics 8, 531-549 (Pubitemid 351472401)
26. Kuperstein, I. et al. (2010) Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO Journal 29, 3408-3420
27. Verdier, Y., Zarandi, M. and Penke, B. (2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. Journal of Peptide Science 10, 229-248 (Pubitemid 38594184)
28. Sze, C.I. et al. (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 56, 933-944
29. Terry, R.D. et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Annals of Neurology 30, 572-580
30. Shankar, G.M. et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 14, 837-842
31. Townsend, M. et al. (2006) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers. Journal of Physiology 572, 477-492
32. Ondrejcak, T. et al. (2010) Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Medicine 12, 13-26
33. Lynch, M.A. (2004) Long-term potentiation and memory. Physiological Reviews 84, 87-136 (Pubitemid 38049877)
34. Martin, S.J. and Morris, R.G. (2002) New life in an old idea: The synaptic plasticity and memory hypothesis revisited. Hippocampus 12, 609-636 (Pubitemid 35363956)
35. Lee, H.G. et al. (2004) The role of metabotropic glutamate receptors in Alzheimer's disease. Acta Neurobiologiae Experimentalis 64, 89-98
36. Bennett, M.R. (2000) The concept of long term potentiation of transmission at synapses. Progress in Neurobiology 60, 109-137
37. Yamin, G. (2009) NMDA receptor-dependent signaling pathways that underlie amyloid betaprotein disruption of LTP in the hippocampus. Journal of Neuroscience Research 87, 1729-1736
38. Texido, L. et al. (2011) Amyloid beta peptide oligomers directly activate NMDA receptors. Cell Calcium 49, 184-190
39. Rammes, G. et al. (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990 21
40. Bordji, K., Becerril-Ortega, J. and Buisson, A. (2011) Synapses, NMDA receptor activity and neuronal Abeta production in Alzheimer's disease. Reviews in the Neurosciences 22, 285-294
41. Derkach, V.A. et al. (2007) Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nature Reviews. Neuroscience 8, 101-113 (Pubitemid 46151040)
42. Lau, C.G. and Zukin, R.S. (2007) NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nature Reviews. Neuroscience 8, 413-426 (Pubitemid 46789232)
43. Paoletti, P. and Neyton, J. (2007) NMDA receptor subunits: Function and pharmacology. Current Opinion in Pharmacology 7, 39-47 (Pubitemid 46238036)
44. Wang, H.W. et al. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Research 924, 133-140
45. Roselli, F. et al. (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. Journal of Neuroscience 25, 11061-11070 (Pubitemid 43089551)
46. Shankar, G.M. et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. Journal of Neuroscience 27, 2866-2875 (Pubitemid 46438992)
47. Deshpande, A. et al. (2009) A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. Journal of Neuroscience 29, 4004-4015
48. Ranicke, R. et al. (2011) Early neuronal dysfunction by amyloid [beta] oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiology of Aging 32, 2219-2228
49. Decker, H. et al. (2010) Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. Journal of Neuroscience 30, 9166-9171
50. De Felice, F.G. et al. (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-Daspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. Journal of Biological Chemistry 282, 11590-11601 (Pubitemid 47100810)
51. 2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47, 264-272
52. Pelkey, K.A. et al. (2002) Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron 34, 127-138 (Pubitemid 34270704)
53. Venkitaramani, D.V. et al. (2007) Beta-amyloid modulation of synaptic transmission and plasticity. Journal of Neuroscience 27, 11832-11837 (Pubitemid 350072092)
54. Kurup, P. et al. (2010) Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. Journal of Neuroscience 30, 5948-5957
55. Zhang, Y. et al. (2010) Genetic reduction of striatalenriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 107, 19014-19019
56. Zieminska, E. and Lazarewicz, J.W. (2006) Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: The role ofNMDAand group I metabotropic glutamate receptors. Acta Neurobiologiae Experimentalis 66, 301-309 (Pubitemid 46114713)
57. Chin, J.H. et al. (2007) Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: Involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. Journal of Neuroscience 27, 9262-9269 (Pubitemid 47358220)
58. Albasanz, J.L. et al. (2005) Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiology of Disease 20, 685-693 (Pubitemid 41619345)
59. Bortolotto, Z.A. et al. (2005) The regulation of hippocampal LTP by the molecular switch, a form of metaplasticity, requires mGlu5 receptors. Neuropharmacology 49(Suppl 1), 13-25 22 (Pubitemid 41115889)
60. Jia, Z. et al. (1998) Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learning and Memory 5, 331-343 (Pubitemid 29115263)
61. Bruno, V. et al. (2000) Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39, 2223-2230 (Pubitemid 30642765)
62. Karanian, D.A. et al. (2006) 3-Nitropropionic acid toxicity in hippocampus: Protection through Nmethyl- D-aspartate receptor antagonism. Hippocampus 16, 834-842 (Pubitemid 44650901)
63. Winblad, B. et al. (2007) Memantine in moderate to severe Alzheimer's disease: A meta-analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders 24, 20-27 (Pubitemid 46985287)
64. Schneider, L.S. et al. (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Archives of Neurology 68, 991-998
65. Lindstrom, J.M. (2003) Nicotinic acetylcholine receptors of muscles and nerves: Comparison of their structures, functional roles, and vulnerability to pathology. Annals of the New York Academy of Sciences 998, 41-52 (Pubitemid 37194146)
66. Arneric, S.P., Holladay, M. andWilliams, M. (2007) Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. Biochemical Pharmacology 74, 1092-1101 (Pubitemid 47417924)
67. D'Andrea, M.R. and Nagele, R.G. (2006) Targeting the alpha 7 nicotinic acetylcholine receptor toreduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Current Pharmaceutical Design 12, 677-684
68. Gotti, C. et al. (2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiology of Disease 23, 481-489 (Pubitemid 44097037)
69. Martin-Ruiz, C.M. et al. (1999) Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. Journal of Neurochemistry 73, 1635-1640 (Pubitemid 29440166)
70. Sabbagh, M.N. et al. (2006) Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Archives of Neurology 63, 1771-1776 (Pubitemid 44925087)
71. Wang, H.Y. et al. (2000) Amyloid peptide Abeta(1- 42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. Journal of Neurochemistry 75, 1155-1161
72. Liu, Q., Kawai, H. and Berg, D.K. (2001) beta- Amyloid peptide blocks the response of alpha 7- containing nicotinic receptors on hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America 98, 4734-4739 (Pubitemid 32295045)
73. Buckingham, S.D. et al. (2009) Nicotinic acetylcholine receptor signalling: Roles in Alzheimer's disease and amyloid neuroprotection. Pharmacological Reviews 61, 39-61
74. Nagele, R.G. et al. (2002) Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110, 199-211 (Pubitemid 34214939)
75. Oddo, S. et al. (2005) Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proceedings of theNational Academyof Sciences of the United States of America 102, 3046-3051 (Pubitemid 40299913)
76. Small, D.H. et al. (2007) The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. Journal of Neurochemistry 101, 1527-1538 (Pubitemid 46848846)
77. Fodero, L.R. et al. (2004) Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)- induced increase in the level of acetylcholinesterase in primary cortical neurones. Journal of Neurochemistry 88, 1186-1193 (Pubitemid 38280686)
78. Dineley, K.T. et al. (2002) beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. Journal of Biological Chemistry 277, 25056-25061 (Pubitemid 34951810)
79. Lee, D.H. and Wang, H.Y. (2003) Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. Journal of Neurobiology 55, 25-30 23 (Pubitemid 36396959)
80. Pettit, D.L., Shao, Z. and Yakel, J.L. (2001) beta- Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. Journal of Neuroscience 21, RC120
81. Tozaki, H. et al. (2002) The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. Biochemical and Biophysics Research Communications 294, 42-45 (Pubitemid 34687211)
82. Tong, M. et al. (2011) Role of key aromatic residues in the ligand-binding domain of {alpha}7 nicotinic receptors in the agonist action of {beta}-amyloid. Journal of Biological Chemistry 286, 34373-34381
83. Hernandez, C.M. et al. (2010) Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. Journal of Neuroscience 30, 2442-2453
84. Dziewczapolski, G. et al. (2009) Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. Journal of Neuroscience 29, 8805-8815
85. Mazurov, A., Hauser, T. and Miller, C.H. (2006) Selective alpha7 nicotinic acetylcholine receptor ligands. Current Medicinal Chemistry 13, 1567-1584 (Pubitemid 43821705)
86. McLean, S.L. et al. (2011) Activation of alpha7 nicotinic receptors improves phencyclidineinduced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia. European Neuropsychopharmacology 21, 333-343
87. Liu, Q. et al. (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. Journal of Neuroscience 29, 918-929
88. Levey, A.I. et al. (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. Journal of Neuroscience 11, 3218-3226
89. Wei, J. et al. (1994) m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. Journal of Neurochemistry 63, 815-821
90. Ferrari-DiLeo, G., Mash, D.C. and Flynn, D.D. (1995) Attenuation of muscarinic receptor- G-protein interaction in Alzheimer disease. Molecular and Chemical Neuropathology 24, 69-91
91. Tsang, S.W. et al. (2006) Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiology of Aging 27, 1216-1223 (Pubitemid 44088578)
92. Warpman, U., Alafuzoff, I. and Nordberg, A. (1993) Coupling of muscarinic receptors to GTP proteins in postmortem human brain - Alterations in Alzheimer's disease. Neuroscience Letters 150, 39-43 (Pubitemid 23142321)
93. Flynn, D.D. et al. (1995) Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. Journal of Neurochemistry 64, 1888-1891
94. Anagnostaras, S.G. et al. (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nature Neuroscience 6, 51-58 (Pubitemid 36026332)
95. Levey, A.I. (1996) Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 93, 13541-13546 (Pubitemid 26424154)
96. Thathiah, A. andDeStrooper, B. (2011) The role ofG protein-coupled receptors in the pathology of Alzheimer's disease. Nature Reviews. Neuroscience 12, 73-87
97. Buxbaum, J.D. et al. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proceedings of theNational Academyof Sciences of the United States of America 89, 10075-10078
98. Nitsch, R.M. et al. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307
99. Davis, A.A. et al. (2010) Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. Journal of Neuroscience 30, 4190-4196
100. Caccamo, A. et al. (2006)M1receptors playa central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671-682 (Pubitemid 43290127)
101. Jones, C.K. et al. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. Journal of Neuroscience 28, 10422-10433
102. Shinoe, T. et al. (2005) Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. Journal of Neuroscience 25, 11194-11200 (Pubitemid 43089564)
103. Farber, S.A. et al. (1995) Regulated secretion of betaamyloid precursor protein in rat brain. Journal of Neuroscience 15, 7442-7451 (Pubitemid 3010080)
104. Fisher, A. (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics 5, 433-442 (Pubitemid 351952486)
105. Bymaster, F.P. et al. (1998) Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5- thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. European Journal of Pharmacology 356, 109-119
106. Craft, S. (2007) Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Current Alzheimer Research 4, 147-152 (Pubitemid 46557503)
107. Hoyer, S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. European Journal of Pharmacology 490, 115-125 (Pubitemid 38482165)
108. Perry, T. et al. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxineinduced peripheral sensory neuropathy. Experimental Neurology 203, 293-301 (Pubitemid 46157226)
109. McClean, P.L. et al. (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. Journal of Neuroscience 31, 6587-6594
110. Chakravarthy, B. et al. (2010) Amyloid-beta peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice. Journal of Alzheimers Disease 19, 915-925
111. Gispen, W.H. and Biessels, G.J. (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends in Neurosciences 23, 542-549
112. Zhao, W. et al. (1999) Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. Journal of Biological Chemistry 274, 34893-34902 (Pubitemid 129509536)
113. Zhao, W.Q. and Alkon, D.L. (2001) Role of insulin and insulin receptor in learning and memory. Molecular and Cellular Endocrinology 177, 125-134 (Pubitemid 32506813)
114. Zhao, W.Q. et al. (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB Journal 22, 246-260
115. Moloney, A.M. et al. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiology of Aging 31, 224-243
116. Townsend, M., Mehta, T. and Selkoe, D.J. (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. Journal of Biological Chemistry 282, 33305-33312 (Pubitemid 350159548)
117. Lee, C.C. et al. (2009) Insulin rescues amyloid betainduced impairment of hippocampal long-term potentiation. Neurobiology of Aging 30, 377-387
118. Risner, M.E. et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease. Pharmacogenomics Journal 6, 246-254 (Pubitemid 44137951)
119. Pedersen, W.A. et al. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Experimental Neurology 199, 265-273 (Pubitemid 43928978)
120. Lovshin, J.A. and Drucker, D.J. (2009) Incretinbased therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology 5, 262-269
121. Gengler, S. et al. (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiology of Aging 33, 265-276
122. Steen, E. et al. (2005) Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? Journal of Alzheimers Disease 7, 63-80 (Pubitemid 40387185)
123. Carro, E. et al. (2005) Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. Journal of Neuroscience 25, 10884-10893 (Pubitemid 41692618)
124. Carro, E. et al. (2006) Therapeutic actions of insulinlike growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiology of Aging 27, 1250-1257 (Pubitemid 44088577)
125. Zhao, W.Q. et al. (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. Journal of Biological Chemistry 284, 18742-18753
126. Qiu,W.Q. and Folstein, M.F. (2006) Insulin, insulindegrading enzyme and amyloid-beta peptide in Alzheimer's disease: Review and hypothesis. Neurobiology of Aging 27, 190-198 (Pubitemid 43038542)
127. Qiu, W.Q. et al. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid betaprotein by degradation. Journal of Biological Chemistry 273, 32730-32738 (Pubitemid 28557658)
128. Cooper, G.J. et al. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America 84, 8628-8632 (Pubitemid 18033465)
129. Arispe, N., Pollard, H.B. and Rojas, E. (1993) Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proceedings of the National Academy of Sciences of the United States of America 90, 10573-10577 (Pubitemid 23347084)
130. Woods, S.C. et al. (2006) Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 361, 1219-1235 (Pubitemid 44882937)
131. Lutz, T.A. (2010) The role of amylin in the control of energy homeostasis. American Journal of Physiology. Regul Integr Comp Physiol 298, R1475-1484
132. May, P.C., Boggs, L.N. and Fuson, K.S. (1993) Neurotoxicity of human amylin in rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid-beta neurotoxicity. Journal of Neurochemistry 61, 2330-2333 (Pubitemid 23354099)
133. Tucker, H.M. et al. (1998) Human amylin induces apoptotic' pattern of gene expression concomitant with cortical neuronal apoptosis. Journal of Neurochemistry 71, 506-516 (Pubitemid 28480397)
134. Lim, Y.A. et al. (2008) Human but not rat amylin shares neurotoxic properties with Abeta42 in longterm hippocampal and cortical cultures. FEBS Letters 582, 2188-2194
135. Lim, Y.A. et al. (2010) Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 10, 1621-1633
136. Jhamandas, J.H. and MacTavish, D. (2004) Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons. Journal of Neuroscience 24, 5579-5584 (Pubitemid 38812640)
137. Jhamandas, J.H. et al. (2003) Human amylin actions on rat cholinergic basal forebrain neurons: Antagonism of beta-amyloid effects. Journal of Neurophysiology 89, 2923-2930 (Pubitemid 36682645)
138. Jhamandas, J.H. et al. (2011) Actions of betaamyloid protein on human neurons are expressed through the amylin receptor. American Journal of Pathology 178, 140-149
139. Bierhaus, A. et al. (2005) Understanding RAGE, the receptor for adVanced glycation end products. Journal of Molecular Medicine 83, 876-886 (Pubitemid 41598688)
140. Schmidt, A.M. et al. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of Clinical Investigation 108, 949-955 (Pubitemid 32946067)
141. Yan, S.D. et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691 (Pubitemid 26282167)
142. Schmidt, A.M. et al. (2009) The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Current Opinion in Investigational Drugs 10, 672-680
143. Yan, S.D. et al. (2009) RAGE and Alzheimer's disease: A progression factor for amyloid-betainduced cellular perturbation? Journal of Alzheimers Disease 16, 833-843 26
144. Maczurek, A., Shanmugam, K. and Munch, G. (2008) Inflammation and the redox-sensitive AGERAGE pathway as a therapeutic target in Alzheimer's disease. Annals of the New York Academy of Sciences 1126, 147-151 (Pubitemid 351589288)
145. Sousa, M.M. et al. (2000) Interaction of the receptor for adVanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Laboratory Investigation 80, 1101-1110 (Pubitemid 30483229)
146. Origlia, N. et al. (2010) Microglial receptor for adVanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. Journal of Neuroscience 30, 11414-11425
147. Han, S.H., Kim, Y.H. and Mook-Jung, I. (2011) RAGE: The beneficial and deleterious effects by diverse mechanisms of actions. Molecules and Cells 31, 91-97
148. Jeynes, B. and Provias, J. (2008) Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Current Alzheimer Research 5, 432-437
149. Deane, R. et al. (2003)RAGEmediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine 9, 907-913 (Pubitemid 36889934)
150. Origlia, N. et al. (2008) Receptor for adVanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. Journal of Neuroscience 28, 3521-3530 (Pubitemid 351469321)
151. Chen, X. et al. (2007) RAGE: A potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Current Molecular Medicine 7, 735-742
152. Deane, R., Wu, Z. and Zlokovic, B.V. (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631 (Pubitemid 39458354)
153. Mackic, J.B. et al. (2002) Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascular Pharmacology 38, 303-313 (Pubitemid 36398252)
154. Martel, C.L. et al. (1996) Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Neuroscience Letters 206, 157-160 (Pubitemid 26096445)
155. Zhang, H. et al. (2008) Role of soluble receptor for adVanced glycation end products on endotoxin-induced lung injury. American Journal of Respiratory and Critical Care Medicine 178, 356-362
156. Raucci, A. et al. (2008)Asoluble form of the receptor for adVanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membranebound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB Journal 22, 3716-3727
157. Emanuele, E. et al. (2005) Circulating levels of soluble receptor for adVanced glycation end products in Alzheimer disease and vascular dementia. Archives of Neurology 62, 1734-1736 (Pubitemid 41626671)
158. [No authors listed] TransTech PharmaTTP488, Alzheimer's Disease. www.ttpharma.com/ pipeline.rage.antagonists.html
159. Coulson, E.J. (2006) Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? Journal of Neurochemistry 98, 654-660 (Pubitemid 44051267)
160. Bothwell, M. (1991) Keeping track of neurotrophin receptors. Cell 65, 915-918 (Pubitemid 121001678)
161. Chao, M.V. and Hempstead, B.L. (1995) p75 and Trk: A two-receptor system. Trends in Neurosciences 18, 321-326
162. Ibanez, C.F. et al. (1992) Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product. Cell 69, 329-341
163. Ip, N.Y. et al. (1993) Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron 10, 137-149 (Pubitemid 23079537)
164. Barker, P.A. (2004) p75NTR is positively promiscuous: Novel partners and new insights. Neuron 42, 529-533 27 (Pubitemid 38639874)
165. Nykjaer, A. et al. (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427, 843-848 (Pubitemid 38297746)
166. Wang, K.C. et al. (2002) P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420, 74-78 (Pubitemid 35291442)
167. Hu, X.Y. et al. (2002) Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Experimental Neurology 178, 104-111
168. Ginsberg, S.D. et al. (2006) Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. Journal of Neurochemistry 97, 475-487
169. Counts, S.E. and Mufson, E.J. (2005) The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. Journal of Neuropathology and Experimental Neurology 64, 263-272 (Pubitemid 40489553)
170. Yaar, M. et al. (1997) Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. Journal of Clinical Investigation 100, 2333-2340 (Pubitemid 27500157)
171. Knowles, J.K. et al. (2009) The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. Journal of Neuroscience 29, 10627-10637
172. Sotthibundhu, A. et al. (2008) Beta-amyloid(1-42) inducesneuronaldeath throughthep75neurotrophin receptor. Journal of Neuroscience 28, 3941-3946
173. Perini, G. et al. (2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. Journal of Experimental Medicine 195, 907-918 (Pubitemid 34286761)
174. Rabizadeh, S. et al. (1994) Expression of the lowaffinity nerve growth factor receptor enhances betaamyloid peptide toxicity. Proceedings of the National Academy of Sciences of the United States of America 91, 10703-10706
175. Costantini, C. et al. (2005) Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in beta-amyloid peptidedependent cell death. Journal of Molecular Neuroscience 25, 141-156 (Pubitemid 41389355)
176. Mufson, E.J. et al. (2002) Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. Journal of Comparative Neurology 443, 136-153 (Pubitemid 34052063)
177. Jaffar, S. et al. (2001) Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: Alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Experimental Neurology 170, 227-243 (Pubitemid 32758676)
178. Bengoechea, T.G. et al. (2009) p75 reduces beta-amyloid-induced sympathetic innervation deficits in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 106, 7870-7875
179. Wang, Y.J. et al. (2011) 75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. Journal of Neuroscience 31, 2292-2304
180. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356 (Pubitemid 34790756)
181. Morgan, D. et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (Pubitemid 32101645)
182. Rinne, J.O. et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebocontrolled, ascending-dose study. Lancet Neurology 9, 363-372
183. Tomita, T. (2009) Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Review of Neurotherapeutics 9, 661-679
184. Augelli-Szafran, C.E. et al. (2010) Discovery of notch-sparing gamma-secretase inhibitors. Current Alzheimer Research 7, 207-209